Improved survival with continuation of statins in bacteremic patients by Pawar, Ajinkta M. et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2018
Improved survival with continuation of statins in
bacteremic patients
Ajinkta M. Pawar
University of Rhode Island
Kerry L. LaPlante pharmD
university of Rhode Island, kerrylaplante@uri.edu
See next page for additional authors
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Pawar, A. M., LaPlante, K. L., Timbrook, T. T., & Caffrey, A. R. (2018). Improved survival with continuation of statins in bacteremic
patients. SAGE Open Medicine. https://doi.org/10.1177/2050312118801707
Available at: https://doi.org/10.1177/2050312118801707
Authors
Ajinkta M. Pawar, Kerry L. LaPlante pharmD, Tristan T. Timbrook, and Aisling R. Caffrey
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/138
SAGE Open Medicine
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, 
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open 
Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
https://doi.org/10.1177/2050312118801707
SAGE Open Medicine
Volume 6: 1 –7
© The Author(s) 2018
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1 77/205 3121 8 017
journals.sagepub.com/home/smo
Introduction
Statins have been associated with improved survival among 
patients with infections,1–7 in meta-analyses,8,9 randomized 
trials, and observational studies.4,5,7,10 The proposed pleio-
tropic effects with statins, including a reduced inflammatory 
response,11,12 suggest that the critical period of exposure 
would be from time of onset of infection through the initial 
period of antibiotic therapy.5,10,13 Importantly, that period of 
onset is likely to occur outside of the healthcare setting, and 
therefore there will be a delay between onset and presenta-
tion to receive care. In previous research, definitions of 
statin exposure vary widely between studies, tend to be 
overly broad, and rarely take into account statin therapy 
adherence.3–5 This study sought to evaluate the impact of 
statin continuation during hospital admission compared 
with non-continuation, in a cohort of adherent statin users.
Methods
A retrospective cohort study design was used to assess inpa-
tient mortality among adherent statin users. This study was 
conducted using de-identified Optum ClinformaticsTM 
(OptumInsight, Eden Prairie, MN) with matched Premier 
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Objectives: Varying statin exposures in bacteremic patients have different impacts on mortality. Among patients 
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Hospital data (1 October 2009–31 March 2013), which is an 
administrative claims database from a large commercial 
health plan (Optum Clinformatics) matched with hospital 
data (Premier). Included in the analysis were adult patients 
(>18 years) with a primary diagnosis of bacteremia 
(International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) codes 003.1, 020.2, 
022.3, 036.2, 038.0, 038.1, 038.10–038.12, 038.19, 038.2, 
038.3, 038.40–038.44, 038.49, 038.8, 038.9, 054.5, 449, 
771.81, 995.91, 995.92, and 790.7).14 We only included 
patients with hospital admissions between 1 April 2010 and 
31 March 2013, to allow for a continuous enrollment period 
of 6 months prior to admission. Antibiotic therapy for each 
patient during the hospital stay was assessed. Patients who 
received at least 2 consecutive days of at least one antibiotic 
therapy for bacteremia15–18 within the first 3 days of the 
admission were included. For patients with multiple admis-
sions for bacteremia, only the first admission was included. 
Medication use was identified from both outpatient prescrip-
tions and medications given during the hospital stay. 
Charlson and Elixhauser comorbidity scores were defined 
using diagnosis codes.14
Using pharmacy claims, we identified prevalent statins 
users demonstrating adherence to their statin therapy, which 
was defined as patients who, irrespective of their statin ini-
tiation time, had at least 90 days of continuous statin expo-
sure (i.e. atorvastatin, lovastatin, pravastatin, rosuvastatin, 
and simvastatin) in the 90 days prior to hospitalization. In 
terms of adherence measures, the proportion of days covered 
was therefore 100% for all included patients, at least 90 days 
of supply dispensed in the 90 days prior to admission. The 
proportion of days covered (PDC) of ⩾80% is commonly 
considered as good adherence for statins.19,20 Statin exposure 
was further categorized as statin continuation, with at least 
5 days of statin therapy after admission, and non-continua-
tion after admission. Inpatient mortality was defined as death 
occurring during the hospital stay.
To identify baseline differences between the statin con-
tinuation and non-continuation groups, we reviewed demo-
graphic and clinical data including current and prior 
comorbidities.14 For categorical variables, if the assumptions 
for the chi-square test were not met, the Fisher’s exact test 
was utilized. For continuous variables, the non-parametric 
Wilcoxon Rank Sum test was used.
We developed a propensity score for statin continuation 
versus non-continuation. The propensity score was therefore 
the predicted probability of statin therapy continuation, as 
calculated from the baseline covariates included in an uncon-
ditional logistic regression model which was built with man-
ual backward elimination.21–23 Patients from the statin 
continuation and non-continuation groups were stratified by 
propensity score quintile to achieve homogeneity between 
exposure groups within quintiles of the predicted probability 
of statin continuation.24 To evaluate the association of con-
tinued statin use and in-hospital mortality, we used a Cox 
proportional hazards model. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute, Cary, NC) 
and statistical significance was considered a p-value of 
⩽0.05. This study was reviewed and approved as exempt by 
the University of Rhode Island’s Institutional Review Board.
Results
We identified 633 patients who met our inclusion and exclu-
sion criteria (Figure 1). This included 232 patients with statin 
continuation and 401 with non-continuation. In comparing 
the statin continuation and non-continuation groups (Table 
1), age (median 62 vs 61 years) and gender (43% vs 44% 
females) were similar. The median Charlson comorbidity 
index during admission (2.0 vs 2.0, p = 0.57; Table 2) and dur-
ing the 6 months prior to admission (3.0 vs 3.0, p = 0. 97) was 
the same in both the groups. Admission from the emergency 
room occurred for 97% of patients with statin continuation 
and 95% with non-continuation (p = 0.29). Marital status, 
race, region, and admitting physician specialty were also sim-
ilar between the statin continuation versus non-continuation 
groups. Simvastatin (53.2%) and atorvastatin (33.8%) were 
the most commonly used statins. Inpatient mortality was sig-
nificantly lower (2.59% vs 10.97%, p = 0.0002) and length of 
stay was higher (median 6.0, interquartile range (IQR) 5.0–
9.0 vs 5.0 days, IQR 3.0–9.0, p < 0.0001) in those continuing 
statins compared with those not continuing. The final propen-
sity score model c-statistic was 0.88, suggesting a strong 
model for predicting the probability of statin continuation.23 
Among bacteremic patients with adherent statin use prior to 
Figure 1. Study cohort identification.
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admission, the propensity score adjusted Cox proportional 
hazards regression model evaluating time to inpatient mortal-
ity demonstrated significantly lower inpatient mortality 
among those continuing statin therapy (hazard ratio (HR) 
0.25, 95% CI 0.08–0.79) compared with those not continuing 
after admission.
Discussion
In this retrospective cohort study among privately insured 
patients with bacteremia, we observed higher survival among 
the statin continuation group compared with the non-contin-
uation group. These results support statin continuation 
through the period of inflammation, as the inflammatory 
response has been found to be lower among patients taking 
statins around the time the infection develops.25,26 The 
specific mechanism by which mortality is reduced among 
statin users with bacteremic infections still remains unde-
fined, however, a proposed mechanism has been the modera-
tion of the overall inflammatory response.27 Other previously 
observed anti-inflammatory effects with statins have 
included lowering of C-reactive protein (CRP), chemokine 
release (MCP-1, RANTES), cytokines (IL-1β, TNF α, IL-6, 
IL-8), and adhesion molecules (P-selectin, VLA 4, CD11a, 
CD11b, CD18).28,29 Statins may also have a direct antimicro-
bial effect,30 and possible antibacterial activity of statins 
against a variety of pathogens may be attributed to their abil-
ity to suppress cell growth, and to promote apoptosis.31–33
Contrary to our findings, a recent randomized controlled 
trial (RCT) did not observe benefits of statin continuation on 
inflammatory parameters and sepsis among adherent statin 
users.34 However, the aforementioned study has several 
Table 1. Demographic and hospitalization-related characteristics among adherent statin users prior to admission.
Characteristics Statin continuation (N = 232) Non-continuation (N = 401) p value
N
/median
%
/IQR
N
/median
%
/IQR
Age (years) 62 55–76 61 56–68 0.1928
Gender 0.6749
 Female 99 42.67 178 44.39
 Male 133 57.33 223 55.61
Race 0.8387
 Black 17 7.3 34 8.5
 Other 33 14.2 53 13.2
 White 182 78.5 314 78.3
Census region 0.1168
 East North Central 45 19.4 57 14.21
 East South Central 5 2.16 5 1.25
 Middle Atlantic 10 4.31 21 5.24
 Mountain 13 5.60 22 5.49
 New England 7 3.02 5 1.25
 Pacific 27 11.64 32 7.98
 South Atlantic 64 27.59 153 38.15
 West North Central 27 11.64 45 11.22
 West South Central 34 14.66 61 15.21
Admission Type 0.2932
 Emergency 225 96.98 382 95.26
 Non-emergency 7 3.02 19 4.74
Admitting physician facility 0.7205
 Intensive care/surgery 8 3.45 18 4.49
 Medicine 93 40.09 167 41.65
 Other 131 56.47 216 53.87
Diagnosis-related group (DRG) description 0.1988
 Non-ventilation 224 96.55 378 94.26
 Ventilation 8 3.45 23 5.74
Hospital admission year 0.2553
 2010 41 17.67 85 21.20
 2011 95 40.95 143 35.66
 2012 96 41.38 173 43.15
Data are median and interquartile range (IQR) or number and percent of patients.
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methodological issues as pointed out in a correspondence by 
Bostock and Vizcaychipi,35 including a vague primary end-
point, lack of information regarding previous statin therapy 
duration, and use of the Mann–Whitney test to evaluate the 
matched groups. The limitations of a number of previous 
studies evaluating protective effects of statins were (a) con-
trol for few confounders,2,7,10,27,36 (b) lack of information 
about pre-hospitalization medication use,10,36,37 (c) combined 
incident and adherent statin use,2,27,37 and (d) combined 
pre-hospital and post-hospital use.37,38 These limitations may 
explain the conflicting findings between studies in regard to 
the impact of statin use on mortality among patients with 
infections.
In terms of contrasting results between studies assessing 
the effects of statin continuation, a prospective cohort study 
conducted in Spain evaluated the survival benefits with sta-
tin use in S. aureus bacteremic (SAB) patients with at least 
30 days prior statin use and continuation until SAB 
Table 2. Clinical characteristics and health service utilization among adherent statin users prior to admission.
Characteristics Statin continuation 
(N = 232)
Non-continuation 
(N = 401)
p value 
N
/median
%
/IQR
N
/median
%
/IQR
Comorbidities (during admission)
 Charlson score (median and IQR) 2 1–4 2 0–3 0.5708
 Elixhauser score (median and IQR) 4 3–6 4 3–6 0.3973
 Chronic renal disease 61 26.29 78 19.45 0.0451
 Coagulation and hemorrhagic disorders 27 11.64 84 20.95 0.0030
 Coagulopathy 25 10.78 75 18.70 0.0084
 Congestive heart failure nonhypertensive 64 27.59 60 14.96 0.0001
 Coronary atherosclerosis and other heart diseases 87 37.50 115 28.68 0.0218
 Diabetes mellitus with complication 61 26.29 69 17.21 0.0064
 Dyslipidemia including hyperlipidemia 161 69.40 208 51.87 <0.0001
 Infective arthritis 15 6.47 11 2.74 0.0230
 Liver disease 12 5.17 47 11.72 0.0063
 Malignant neoplasm 6 2.59 54 13.47 <0.0001
 Metastatic cancer 3 1.29 30 7.48 0.0003
 Mild liver disease 11 4.74 40 9.98 0.0197
 Obesity 69 29.74 83 20.70 0.0103
 Poisoning by medication and drugs 20 8.62 69 17.21 0.0027
 Solid tumor without metastasis 5 2.16 49 12.22 <0.0001
 Weight loss 22 9.48 68 16.96 0.0095
Medication use (during admission)
 Anti-hypertensive medication 207 89.22 274 68.33 <0.0001
Comorbidities (6 months prior to admission)
 Charlson score (median and IQR) 3 1–5 3 2–6 0. 9720
 Elixhauser score (median and IQR) 6 5–9 5 3–9 0.7992
 History of any cancer 35 15.09 102 25.44 0.0023
 History of chronic kidney disease 47 20.26 57 14.21 0.048
 History of condition with dizziness or vertigo 32 13.79 25 6.23 0.0014
 History of dyslipidemia including hyperlipidemia 175 75.43 263 65.59 0.0097
 History of history of other Immunocompromise 14 6.03 46 11.47 0.0244
 History of maintenance chemotherapy radiotherapy 8 3.45 43 10.72 0.0012
 History of malignant neoplasm 24 10.34 76 18.95 0.0042
 History of metastatic cancer 7 3.02 37 9.23 0.0031
  History of other and ill-defined cerebrovascular 
diseases
15 6.47 12 2.99 0.0372
 History of other eye disorder 27 11.64 28 6.98 0.0451
 History of solid tumor without metastasis 24 10.34 74 18.45 0.0066
Medication use history (6 months prior to admission)
 History of diabetic medication 74 31.9 112 27.93 0.0081
 History of anti-hypertensive medication 199 85.78 317 79.05 0.0357
Data are median and interquartile range (IQR) or number and percent of patients.
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diagnosis, and did not observe significant protective effect of 
statins on 30-day mortality (odds ratio (OR)  =  0.35; 95% CI: 
0.10–1.23; p  = 0.10).4 Conversely, a recent multicenter RCT 
conducted among 250 critically ill patients with severe sep-
sis (123 statins, 127 placebo) reported a significantly lower 
28-day mortality rate in the adherent statin continuation 
group compared with the placebo group (5% vs 28%; 
p = 0.01).39 A retrospective cohort study conducted at a 
Veterans Affairs Medical Center in Washington among bac-
teremic patients, identified a therapeutic benefit with statin 
continuation (n = 35 vs 353, adjusted OR 0.13, 95% CI 0.02–
0.99) compared with non-statin users.7
The results of this study have potential limitations. In our 
primary analysis, we evaluated adherent statin users, poten-
tially leading to healthy user bias. We used time-varying ana-
lytic methods to mitigate the impact of survival bias. However, 
in the comparison group, one death was observed within the 
first 5 days of admission, and had this patient been excluded, 
the HR may have been closer to 1. Furthermore, the sample 
size of our study was small and we could not study the protec-
tive effects of each statin separately due to the small numbers. 
The effect of statins on inpatient mortality in patients with 
sepsis may be different for individual statins.40 We also could 
not assess the dose-dependent effects, changes in statin ther-
apy (drug or dose) prior to admission, at admission, or during 
the admission, or the effects of adherence due to low sample 
sizes. In our review of statin doses, dispensing quantity in 
incident users mostly reflected moderate to high doses. As we 
used an administrative claims database for our analysis, we 
assumed outpatient statin exposure to be equivalent to filling 
a prescription. Furthermore, there is a possibility of statins 
having a different impact on clinical outcomes based on the 
causative pathogen, since the mechanism of action is not 
exactly known and it may vary for different pathogens. 
Microbiology data was not available for a potential causative 
pathogen, but we identified organisms using ICD-9 codes, 
where available. Bacteremic treatment varies by organism 
type and we were only able to use general inclusion criteria of 
having received an antibiotic which may be used for bactere-
mia.15–18 Since we only evaluated a general bacteremic popu-
lation, our results may not be generalized to pathogen-specific 
bacteremias. Despite using propensity scores to control for 
confounding, we could not control for unmeasured confound-
ing. Specifically, bacteremia severity scores and bacteremia 
source were not available from the data source, although we 
did control for ventilation status and sepsis severity using 
diagnosis-related groups (DRG).
In conclusion, our retrospective cohort study quantified 
the effect of adherent statin continuation on clinical out-
comes such as inpatient mortality and hospital length of stay 
among bacteremic patients in a real-world clinical popula-
tion. We observed significant reduction in inpatient morality 
among adherent statin continuation for at least the first few 
days after hospitalization compared with non-continuation 
during admission. Our results possibly hint at the necessity 
of statin exposure through the period of inflammation devel-
opment as the inflammatory response has been found to be 
decreasing among patients consuming statins at the same 
time as developing infection.25,26 Further unaddressed ques-
tions related to this research question include appropriate 
statin exposure time and duration needed for the maximum 
clinical benefits, and differences in the magnitude of each 
statin’s protective effects.
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